Improved relapse free survival in patients with poor prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high dose melphalan followed by high dose etoposide and hematopoietic rescue

Bone Marrow Transplant. 1991:7 Suppl 2:95.

Authors

S Burdach¹, C Peters, M Paulussen, W Nürnberger, R Wurm, P Wernet, D Dilloo, R Voehringer, H Gadner, U Göbel, et al.

Affiliation

¹ Bone Marrow Transplantation Program, Heinrich Heine University Medical Center, Düsseldorf, FRG.

PMID: 1678978

No abstract available

Publication types

Clinical Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Transplantation* / mortality
Bone Neoplasms / drug therapy
Bone Neoplasms / mortality
Bone Neoplasms / radiotherapy
Bone Neoplasms / surgery
Bone Neoplasms / therapy*
Combined Modality Therapy
Etoposide / administration & dosage
Graft Survival
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Immunologic Factors / therapeutic use
Melphalan / administration & dosage
Radiotherapy Dosage
Remission Induction
Sarcoma, Ewing / drug therapy
Sarcoma, Ewing / mortality
Sarcoma, Ewing / radiotherapy
Sarcoma, Ewing / surgery
Sarcoma, Ewing / therapy*
Survival Rate
Whole-Body Irradiation* / adverse effects

Substances

Immunologic Factors
Etoposide
Granulocyte-Macrophage Colony-Stimulating Factor
Melphalan